Other
Neoplasm by Special Category
CI-CAN-00000004Explore in graph →
Non-malignant21,340 active trials259 approved drugs3,859 evidence items
- NCIt
- C7062
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000004Explore in graph →
Clinical trials
95,701 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04568304 | A Study Evaluating Toripalimab Injection Combined With Standard Chemotherapy as a First-line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma | withdrawn | Phase 3 | 0 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Jul 9, 2026 | clinicaltrials |
| NCT00006344 | Radiation Therapy in Preventing Brain Metastases in Patients With Small Cell Lung Cancer | withdrawn | Phase 3 | 0 | Virginia Commonwealth UniversityOTHER | 1 | Jun 30, 2026 |
| clinicaltrials |
| NCT07524257 | Phase 3 Study of Nogapendekin Alfa Inbakicept Plus Standard of Care vs Standard of Care in First-Line Advanced or Metastatic NSCLC | withdrawn | Phase 3 | 0 | ImmunityBio, Inc.INDUSTRY | 0 | Jun 22, 2026 | clinicaltrials |
| NCT07428369 | A Study of Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly Diagnosed Multiple Myeloma (NDMM)(LINKER-MM8) | withdrawn | Phase 2 / Phase 3 | 0 | Regeneron PharmaceuticalsINDUSTRY | 0 | Jun 18, 2026 | clinicaltrials |
| NCT07551544 | ANKTIVA Plus BCG Versus BCG Monotherapy In Participants With BCG-Naïve/BCG-Exposed High-Grade Non-Muscle Invasive Papillary Bladder Cancer | withdrawn | Phase 3 | 0 | ImmunityBio, Inc.INDUSTRY | 0 | May 19, 2026 | clinicaltrials |
| NCT04105374 | Testing the Addition of an Anti-cancer Viral Gene Therapy, Toca 511/Toca FC, to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed Glioblastoma | withdrawn | Phase 2 / Phase 3 | 0 | NRG OncologyOTHER | 0 | May 7, 2026 | clinicaltrials |
| NCT06313996 | A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma | withdrawn | Phase 3 | 0 | Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyINDUSTRY | 0 | Mar 18, 2026 | clinicaltrials |
| NCT06585969 | A Randomised Trial Comparing Trastuzumab Deruxtecan to CDK4/6 Inhibitors in Non-luminal A, ER-positive/HER2-low Metastatic Breast Cancer(DISCORDANT) | withdrawn | Phase 3 | 0 | Danish Breast Cancer Cooperative GroupOTHER | 0 | Feb 12, 2026 | clinicaltrials |
| NCT06866951 | A Clinical Study Comparing Chemotherapy Combined With PD-1 Inhibitor Versus Concurrent Chemoradiotherapy in Cervical Cancer Patients With Positive Lymph Nodes After Surgery: A Multicenter Randomized Controlled Clinical Trial | withdrawn | Phase 2 / Phase 3 | 0 | Women's Hospital School Of Medicine Zhejiang UniversityOTHER | 1 | Dec 16, 2025 | clinicaltrials |
| NCT07084909 | Piflufolastat F 18 PET/CT in Patients With Suspected, or at High Risk for Metastatic ccRCC(HARRIER) | withdrawn | Phase 2 / Phase 3 | 0 | Lantheus Medical ImagingINDUSTRY | 1 | Dec 10, 2025 | clinicaltrials |
| NCT07092475 | The Impact of Intraoperative Methadone on Postoperative Opioid Use | withdrawn | Phase 3 | 0 | University of UtahOTHER | 1 | Nov 26, 2025 | clinicaltrials |
| NCT02446652 | Evaluation of TRANSKRIP ® Plus Chemotherapy in Recurrent-Persistent Cervical Cancer | withdrawn | Phase 3 | 0 | National Institute of CancerologíaOTHER_GOV | 1 | May 29, 2025 | clinicaltrials |
| NCT06795178 | Efficacy, Safety, and Pharmacokinetics of FP-014, 11.25 mg in Patients With Advanced Prostate Cancer(KATANA E3M) | withdrawn | Phase 3 | 0 | Foresee Pharmaceuticals Co., Ltd.INDUSTRY | 0 | Apr 27, 2025 | clinicaltrials |
| NCT06795191 | Efficacy, Safety, and Pharmacokinetics of FP-014, 22.5 mg in Patients With Advanced Prostate Cancer(KATANA E6M) | withdrawn | Phase 3 | 0 | Foresee Pharmaceuticals Co., Ltd.INDUSTRY | 0 | Apr 27, 2025 | clinicaltrials |
| NCT01345084 | Study Comparing Radiation Therapy and Chemotherapy With or Without Nimotuzumab(NICAP) | withdrawn | Phase 3 | 0 | Eurofarma Laboratorios S.A.INDUSTRY | 1 | Mar 28, 2025 | clinicaltrials |
| NCT03632798 | Avastin Plus Chemotherapy vs. Avastin Plus Chemotherapy Guided by Cancer Stem Cell Test in Recurrent Ovarian Cancer(ACSCO) | withdrawn | Phase 3 | 0 | Cordgenics, LLCINDUSTRY | 1 | Feb 12, 2025 | clinicaltrials |
| NCT02883361 | Motivational Enhancement Therapy to Improve Adherence to Aromatase Inhibitors(MI for AIs) | withdrawn | Phase 2 / Phase 3 | 0 | University of CalgaryOTHER | 1 | Dec 5, 2024 | clinicaltrials |
| NCT04488159 | Immunoscore As Decision Guidance for Adjuvant Chemotherapy in Colon Cancer(iMAGINE) | withdrawn | Phase 3 | 0 | Johannes Laengle, MD, PhDOTHER | 1 | Sep 20, 2024 | clinicaltrials |
| NCT06370871 | Brightline-3: A Study to Find Out Whether Brigimadlin in Combination With Ezabenlimab Helps People With Advanced Soft Tissue Sarcoma | withdrawn | Phase 3 | 0 | Boehringer IngelheimINDUSTRY | 0 | Jul 17, 2024 | clinicaltrials |
| NCT06232707 | A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)(ALUMMINATE) | withdrawn | Phase 3 | 0 | CelgeneINDUSTRY | 27 | May 31, 2024 | clinicaltrials |
| NCT05403580 | Olanzapine for the Treatment of Chronic Nausea and/or Vomiting in Patients With Advanced Cancer | withdrawn | Phase 3 | 0 | Mayo ClinicOTHER | 0 | May 6, 2024 | clinicaltrials |
| NCT06301308 | A Novel Application of 2% Lidocaine Injection for Male Rigid cycstoscopy-a Patient-blinded Randomised Trial | withdrawn | Phase 3 | 0 | Second Xiangya Hospital of Central South UniversityOTHER | 1 | Apr 24, 2024 | clinicaltrials |
| NCT06205290 | A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies | withdrawn | Phase 3 | 0 | Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyINDUSTRY | 11 | Apr 2, 2024 | clinicaltrials |
| NCT05711628 | A Trial Comparing Chemotherapy Versus Novel Immune Checkpoint Inhibitor (Pembrolizumab) Plus Chemotherapy in Treating Relapsed/Refractory Classical Hodgkin Lymphoma | withdrawn | Phase 3 | 0 | National Cancer Institute (NCI)NIH | 0 | Mar 20, 2024 | clinicaltrials |
| NCT05474690 | A Study Comparing the Efficacy of TCbHP and ECHP-THP in the Neoadjuvant Treatment of HER2-positive Breast Cancer | withdrawn | Phase 3 | 0 | Henan Cancer HospitalOTHER_GOV | 1 | Feb 26, 2024 | clinicaltrials |
| NCT04760288 | A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC).(AcceleRET-MTC) | withdrawn | Phase 3 | 0 | Hoffmann-La RocheINDUSTRY | 1 | Jan 5, 2024 | clinicaltrials |
| NCT02519140 | Assessing How the Viscosity of Submucosal Gel Injections Helps With Endoscopic Mucosal Resections | withdrawn | Phase 3 | 0 | Antonios LikourezosOTHER | 1 | Dec 4, 2023 | clinicaltrials |
| NCT05712941 | Comparison of Letrozole With Lerociclib Versus Letrozole With Placebo Control in Patients With Advanced/Metastatic or Recurrent, Grade 1 or Grade 2 Endometrial Cancer | withdrawn | Phase 3 | 0 | EQRx International, Inc.INDUSTRY | 0 | Nov 3, 2023 | clinicaltrials |
| NCT05771896 | Darolutamide With Radium-223 or Placebo and the Effect on Radiological Progression-Free Survival for Patients With mCSPC(CARE) | withdrawn | Phase 3 | 0 | GenesisCare USAOTHER | 0 | Sep 14, 2023 | clinicaltrials |
| NCT05098327 | Pioglitazone and Insulin Resistance in ADT | withdrawn | Phase 3 | 0 | State University of New York at BuffaloOTHER | 1 | Aug 15, 2023 | clinicaltrials |
| NCT00488605 | H-9926-LCH III: Treatment Protocol of the Third International Study for Langerhans Cell Histiocytosis | withdrawn | Phase 3 | 0 | University of New MexicoOTHER | 1 | Aug 3, 2023 | clinicaltrials |
| NCT05791097 | Study of Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Platinum-based Doublet Chemotherapy as First-line Treatment for Participants With Locally Advanced or Metastatic NSCLC.(AdvanTIG-306) | withdrawn | Phase 3 | 0 | Novartis PharmaceuticalsINDUSTRY | 0 | Jul 24, 2023 | clinicaltrials |
| NCT04466917 | A Study of ABP 215 Versus Bevacizumab in Chinese Subjects With Advanced Non-Squamous Non-Small Cell Lung Cancer | withdrawn | Phase 3 | 0 | AmgenINDUSTRY | 0 | Jul 3, 2023 | clinicaltrials |
| NCT05363644 | BioDFence® G3 For Full Nerve-Sparing Robotic-Assisted Radical Prostatectomy | withdrawn | Phase 3 | 0 | AdventHealthOTHER | 1 | Jun 29, 2023 | clinicaltrials |
| NCT05431179 | A Study of Zilovertamab and Ibrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma | withdrawn | Phase 3 | 0 | Oncternal Therapeutics, IncINDUSTRY | 0 | Apr 21, 2023 | clinicaltrials |
| NCT03742596 | Effect of Probiotics Supplementation on the Side Effects of Radiation Therapy Among Colorectal Cancer Patients | withdrawn | Phase 2 / Phase 3 | 0 | King Hussein Cancer CenterOTHER | 1 | Mar 15, 2023 | clinicaltrials |
| NCT04021082 | CELTIC-1: A Phase 2B Study of Cerdulatinib in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) | withdrawn | Phase 2 / Phase 3 | 0 | Portola PharmaceuticalsINDUSTRY | 0 | Feb 21, 2023 | clinicaltrials |
| NCT05325164 | Methadone for 'Adenocarcinopathic' Pain Treatment(METHADOPT) | withdrawn | Phase 3 | 0 | Ottawa Hospital Research InstituteOTHER | 0 | Dec 5, 2022 | clinicaltrials |
| NCT04943627 | Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA) | withdrawn | Phase 3 | 0 | Agenus Inc.INDUSTRY | 2 | Oct 5, 2022 | clinicaltrials |
| NCT02201381 | Study of the Safety, Tolerability and Efficacy of Metabolic Combination Treatments on Cancer(METRICS) | withdrawn | Phase 3 | 0 | Health Clinics LimitedINDUSTRY | 1 | Jul 18, 2022 | clinicaltrials |
| NCT04796922 | To Evaluate Efficacy and Safety of Parsaclisib Plus Either Rituximab or Obinutuzumab in R/R Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) (CITADEL-302) | withdrawn | Phase 3 | 0 | Incyte CorporationINDUSTRY | 0 | Jul 18, 2022 | clinicaltrials |
| NCT04676243 | Daunorubicin or Idarubicin With Cytarabine Plus Quizartinib vs Physician's Choice in Newly Diagnosed FLT3-ITD+ AML(Q-SOC) | withdrawn | Phase 3 | 0 | University Hospital HeidelbergOTHER | 0 | May 25, 2022 | clinicaltrials |
| NCT04465734 | A Clinical Study to Compare the Efficacy and Safety of HLX10 in Combination With HLX04 Versus Sorafenib as the First-line Treatment in Patients With Locally Advanced or Metastatic HCC | withdrawn | Phase 3 | 0 | Shanghai Henlius BiotechINDUSTRY | 1 | May 5, 2022 | clinicaltrials |
| NCT04806945 | A Phase III Study to Evaluate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy in Patients With Advanced Cervical Cancer | withdrawn | Phase 3 | 0 | Shanghai Henlius BiotechINDUSTRY | 1 | May 5, 2022 | clinicaltrials |
| NCT04849715 | A Study of Parsaclisib, a PI3Kδ Inhibitor, in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma(CITADEL-310) | withdrawn | Phase 3 | 0 | Incyte CorporationINDUSTRY | 0 | Apr 29, 2022 | clinicaltrials |
| NCT04795596 | Secondary Cytoreductive Surgery in Platinum-resistant Recurrent Ovarian Cancers | withdrawn | Phase 2 / Phase 3 | 0 | Menoufia UniversityOTHER | 1 | Apr 15, 2022 | clinicaltrials |
| NCT00255138 | Efficacy of Atomoxetine Therapy Versus Placebo for Cognitive Late Effects | withdrawn | Phase 3 | 0 | Temple UniversityOTHER | 1 | Apr 1, 2022 | clinicaltrials |
| NCT04129320 | Enoblituzumab Plus MGA012 or MGD013 in Squamous Cell Carcinoma of the Head and Neck | withdrawn | Phase 2 / Phase 3 | 0 | MacroGenicsINDUSTRY | 0 | Feb 8, 2022 | clinicaltrials |
Data updated 22 days agoSource updated Jul 9, 2026source: clinicaltrials